UiPath
PATH
$10.79
+2.27%
UiPath, Inc. is a leading provider of an end-to-end enterprise automation platform, operating within the Software - Infrastructure industry. The company is a market leader in Robotic Process Automation (RPA), leveraging computer vision, AI, and APIs to automate repetitive tasks across various business functions and industries. The current investor narrative is intensely focused on whether the company's strong revenue growth can translate into sustainable profitability, with recent news highlighting a stock surge following strong quarterly results and a raised outlook, juxtaposed against ongoing debates about competitive threats from generative AI and its potential in the emerging agentic AI orchestration market.…
PATH
UiPath
$10.79
Related headlines
Investment Opinion: Should I buy PATH Today?
Rating & Thesis: Hold. UiPath presents a compelling fundamental turnaround story trapped in a bearish technical and sentiment backdrop, making it a high-risk, high-potential-reward stock that is not yet a clear Buy. The neutral consensus among analysts (predominantly Hold ratings) aligns with this view, suggesting the stock is fairly valued at current levels as the market awaits clarity on competitive threats.
Supporting Evidence: The Hold rating is supported by four key data points: 1) The attractive forward P/E of 11.6x prices in significant earnings growth from the profitable Q4 ($104.5M net income). 2) Revenue growth remains solid at 13.6% YoY. 3) Gross margins are exceptional at 84.9%, supporting the software model's scalability. 4) The balance sheet is virtually risk-free with a 0.034 debt-to-equity ratio and strong cash generation. However, these positives are counterbalanced by the stock's -39.4% six-month decline and the overhang from generative AI competition.
Risks & Conditions: The two biggest risks invalidating a more bullish stance are sustained revenue deceleration and material market share loss to AI-native competitors. This Hold would upgrade to a Buy if the stock demonstrates sustained quarterly execution by holding QoQ net income above $50 million and revenue growth stabilizes or re-accelerates above 15% YoY, signaling it is weathering the competitive storm. It would downgrade to a Sell if revenue growth decelerates below 10% YoY or the stock breaks decisively below its 52-week low of $9.20. Relative to its own history and the growth/profitability profile, the stock is fairly valued to slightly undervalued, but this discounts the significant competitive uncertainty.
Sign up to view all
PATH 12-Month Price Forecast
The AI assessment is neutral based on a clash between improving fundamentals and deteriorating sentiment. The company's financial health and profitability trajectory are clear positives, but the stock's violent downtrend and the existential competitive narrative create too much uncertainty for a bullish call. The base case (60% probability) of range-bound trading is most likely, as the company must prove its AI-integration strategy over multiple quarters to rebuild investor trust. Confidence is medium due to the binary nature of the competitive threat. The stance would upgrade to bullish on evidence of market share defense and sustained double-digit revenue growth; it would turn bearish on a breakdown below $9.20 or a material guidance reduction.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on UiPath's 12-month outlook, with a consensus price target around $14.03 and implied upside of +30.0% versus the current price.
Average Target
$14.03
5 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
5
covering this stock
Price Range
$9 - $14
Analyst target range
Analyst coverage for UiPath appears limited based on the provided data, with only 5 analysts providing estimates for EPS and revenue. This suggests the stock may have less institutional following than larger peers, which can lead to higher volatility and less efficient price discovery. The estimated EPS average for the forward period is $1.01, with a tight range from $1.01 to $1.02, indicating strong consensus on near-term profitability. Estimated revenue averages $2.07 billion. Insufficient data is available on the consensus price target, Buy/Hold/Sell distribution, or target price range from the provided analyst data set. The institutional ratings list shows recent actions from ten firms, with a mix of Hold/Neutral/Equal-Weight ratings (from BMO, Truist, Morgan Stanley, etc.), one Buy (Canaccord Genuity), and one Underperform (B of A Securities). This pattern suggests a cautious to neutral consensus among covering institutions, with no widespread bullish conviction. The lack of a clear target price range in the data prevents calculating implied upside or downside, but the prevalence of hold-equivalent ratings implies analysts see the stock as fairly valued at current levels, balancing growth potential against competitive and execution risks.
Bulls vs Bears: PATH Investment Factors
The evidence presents a stark contrast between strong company fundamentals and weak market sentiment. The bull case is anchored in UiPath's impressive profitability turnaround, pristine balance sheet, and compelling forward valuation. The bear case is driven by severe technical damage, competitive fears from generative AI, and a clear lack of analyst enthusiasm. Currently, the bearish evidence from price action and sentiment holds greater weight, as the stock's -39.4% six-month decline cannot be ignored. The single most important tension in the investment debate is whether the company's strong execution and profitability (21.7% net margin) can overcome the market's fear that generative AI will render its core RPA technology obsolete. The resolution of this competitive threat will be the primary driver of the stock's re-rating or further decline.
Bullish
- Strong Profitability Turnaround: UiPath has dramatically transitioned to profitability, with Q4 net income of $104.5 million and a net margin of 21.7%, up from a net loss of $22.6 million in Q1 of the same fiscal year. This demonstrates that robust revenue growth is now effectively flowing to the bottom line, a key investor concern.
- Exceptional Balance Sheet & Cash Flow: The company has a fortress balance sheet with a debt-to-equity ratio of 0.034 and $871.6 million in cash. It generated $352.2 million in TTM free cash flow, providing ample resources to fund growth and navigate market volatility without financial risk.
- Attractive Forward Valuation: The stock trades at a forward P/E of 11.6x, a significant discount to its trailing P/E of 24.0x, implying the market expects strong earnings growth. This valuation appears reasonable for a software firm with 13.6% YoY revenue growth and high gross margins of 84.9%.
- Strategic Position in Agentic AI: Recent news highlights UiPath's potential as a leader in the emerging agentic AI orchestration market, leveraging its core RPA foundation. This positions the company to capture a new, high-growth market segment beyond traditional automation.
Bearish
- Severe Long-Term Price Weakness: The stock is in a pronounced downtrend, with a 1-year price change of -16.7% and a 6-month decline of -39.4%. It has underperformed the S&P 500 by -39.5% over the past year, reflecting persistent negative sentiment and fundamental concerns.
- Volatile & Decelerating Revenue Growth: While Q4 revenue grew 13.6% YoY, quarterly revenue has shown lumpiness, and the 6-month price decline of -39.4% suggests the market is pricing in growth deceleration. The stock's sensitivity to earnings is evidenced by its -51.4% maximum drawdown.
- Existential Competitive Threat from GenAI: A key bear narrative, highlighted in recent news, is that generative AI could permanently disrupt or replace traditional RPA workflows. This creates an overhang on UiPath's core market and long-term growth trajectory, pressuring its valuation multiple.
- Lack of Analyst Conviction: Institutional ratings are predominantly Hold/Neutral, with only one Buy (Canaccord) and one Underperform (B of A) among recent actions. This cautious consensus, with limited analyst coverage (5 analysts), suggests a lack of bullish catalysts and weak institutional conviction.
PATH Technical Analysis
The stock is in a pronounced downtrend, with a 1-year price change of -16.7% and a 6-month decline of -39.4%. Currently trading at $10.55, the price sits near the lower end of its 52-week range of $9.20 to $19.84, positioning it at approximately 40% of this range, which suggests a deep value opportunity but also reflects significant fundamental pressure and negative sentiment. Recent momentum shows a short-term bounce with a 1-month gain of 11.4%, but this is against a backdrop of a 3-month loss of -8.9%, indicating the recent uptick may be a technical rebound within a broader bearish trend rather than a confirmed reversal. Key technical levels are clearly defined, with immediate support at the 52-week low of $9.20 and resistance at the 52-week high of $19.84. A decisive break below $9.20 would signal a continuation of the downtrend and potentially trigger further selling, while a sustained move above recent highs near $13.10 would be needed to suggest a more meaningful recovery is underway. The stock's beta of 0.968 indicates its volatility is nearly in line with the broader market, which, combined with a short ratio of 3.28, suggests elevated bearish sentiment but not extreme idiosyncratic risk relative to the S&P 500. The price action has been highly volatile, with a maximum drawdown of -51.4% over the observed period, underscoring the stock's sensitivity to earnings results and shifts in growth sentiment. The recent 1-month relative strength of +11.5% against the SPY's -0.1% loss is a positive divergence, but it follows severe long-term underperformance, including a 1-year relative strength of -39.5%. This mixed picture indicates the stock is attempting to find a bottom, but investor conviction remains fragile.
Beta
0.97
0.97x market volatility
Max Drawdown
-51.4%
Largest decline past year
52-Week Range
$9-$20
Price range past year
Annual Return
-11.8%
Cumulative gain past year
| Period | PATH Return | S&P 500 |
|---|---|---|
| 1m | +5.1% | +2.1% |
| 3m | -9.9% | +12.5% |
| 6m | -32.4% | +12.4% |
| 1y | -11.8% | +26.4% |
| ytd | -32.1% | +10.7% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
PATH Fundamental Analysis
Revenue growth remains robust but has shown volatility on a quarterly basis. The most recent Q4 FY2026 revenue was $481.1 million, representing a 13.6% year-over-year increase. However, examining the sequential quarterly trend from the income statements reveals inconsistency: revenue grew from $356.6M in Q1 to $411.1M in Q3, then jumped to $481.1M in Q4, but this followed a Q4 FY2025 revenue of $423.6M, indicating some quarterly lumpiness. The revenue segment data shows the business is driven by License ($215.9M) and Subscription Services ($251.2M), with Professional Services being a smaller component ($31.6M). Profitability has improved dramatically, transitioning from losses to significant net income. The latest Q4 net income was $104.5 million, yielding a net margin of 21.7%, a stark improvement from a net loss of $22.6 million in Q1 of the same fiscal year. Gross margin remains exceptionally strong at 84.9% in Q4, consistent with the company's software-centric model. The operating margin was 16.7% in Q4, a major recovery from an operating loss in prior quarters, signaling that revenue growth is finally flowing through to the bottom line. The balance sheet is very healthy with strong liquidity and minimal debt. The current ratio is a robust 2.48, and the debt-to-equity ratio is a negligible 0.034, indicating virtually no financial leverage risk. The company generates substantial cash flow, with free cash flow over the trailing twelve months at $352.2 million and operating cash flow of $182.3 million in Q4 alone. This strong cash generation, coupled with $871.6 million in cash at the end of Q4, provides ample resources to fund operations and growth initiatives without needing external financing, significantly de-risking the investment case.
Quarterly Revenue
$481107000.0B
2026-01
Revenue YoY Growth
+0.13%
YoY Comparison
Gross Margin
+0.84%
Latest Quarter
Free Cash Flow
$352160000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is PATH Overvalued?
Given the company's positive net income of $104.5 million in the latest quarter, the primary valuation metric selected is the Price-to-Earnings (PE) ratio. The trailing PE ratio is 24.0x, while the forward PE is significantly lower at 11.6x. This substantial gap implies the market expects a significant acceleration in earnings growth over the next twelve months, likely pricing in the recent trend of expanding profitability. Compared to sector averages, the stock's valuation presents a mixed picture. Its Price-to-Sales ratio of 4.2x and EV-to-Sales of 2.6x are not directly comparable to a provided industry average, but the forward PE of 11.6x appears reasonable for a software company with 13.6% revenue growth and improving margins. The EV-to-EBITDA of 76.7x is elevated, reflecting the company's high depreciation and amortization relative to its market capitalization, which is common for asset-light software firms. Historically, the current trailing PE of 24.0x sits well below the stock's own historical range observed in the data, which has seen periods with PE ratios in the high 90s and even negative figures during loss-making quarters. For instance, the PE ratio was 16.1x as of the Q4 FY2026 financial date. This suggests the stock is trading at a more normalized, if not discounted, valuation relative to its own history, potentially reflecting a market that has recalibrated expectations from pure growth to profitable growth, offering a more balanced risk-reward profile.
PE
24.0x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range -163x~994x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
50.8x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: UiPath's primary financial risk is not leverage or liquidity—its balance sheet is exceptionally strong—but rather earnings volatility and growth sustainability. While Q4 net income was $104.5M, this followed a net loss of $22.6M in Q1 of the same fiscal year, indicating significant quarterly earnings lumpiness that could disappoint investors. Furthermore, the company's valuation (forward P/E of 11.6x) is predicated on continued profitable growth; a deceleration from the current 13.6% YoY revenue growth rate would compress this multiple. Revenue concentration in its License and Subscription segments, while typical for software, creates dependency on renewals and expansion within its existing customer base.
Market & Competitive Risks: The paramount external risk is technological disruption from generative AI, which threatens to automate tasks beyond the structured processes targeted by traditional RPA. This existential competitive overhang is a key reason for the stock's depressed valuation and -39.4% six-month decline. From a valuation perspective, the stock's trailing P/E of 24.0x, while below its own historical peaks, remains susceptible to compression if growth slows or the competitive narrative worsens. Its beta of 0.968 indicates market-correlated volatility, meaning a broader tech selloff would likely drag PATH lower despite its company-specific improvements.
Worst-Case Scenario: The worst-case scenario involves generative AI adoption accelerating faster than UiPath can pivot, leading to mass customer attrition, collapsing revenue growth, and a swift return to sustained losses. This would trigger a wave of analyst downgrades from the current neutral stance and force a valuation re-rating to that of a legacy business. The realistic downside is quantified by the 52-week low of $9.20, which represents a -13% decline from the current price of $10.55. Given the stock's history of a -51.4% maximum drawdown, a breach of the $9.20 support could catalyze a swift move toward the $8.00 range, implying a total potential loss of -24% to -30% from current levels in a severe adverse scenario.
FAQ
The key risks are, in order of severity: 1) Competitive Disruption: Generative AI could make traditional RPA obsolete, threatening the core business (highlighted in recent bearish news). 2) Execution & Growth: Volatile quarterly earnings and a potential deceleration from the current 13.6% revenue growth could crush the valuation multiple. 3) Sentiment & Technical: The stock is in a severe downtrend (-39.4% over 6 months) with high short interest (short ratio 3.28), which can exacerbate selling pressure. 4) Market Risk: With a beta of 0.968, PATH would likely fall in a broad market or tech sector selloff despite company-specific improvements.
The 12-month forecast presents three scenarios with associated probabilities. The Base Case (60% probability) sees the stock trading between $11.00 and $13.50, as steady execution is offset by competitive fears. The Bull Case (25% probability) targets a range of $16.00 to $19.84 (the 52-week high) on successful AI integration and multiple expansion. The Bear Case (15% probability) envisions a re-test of the 52-week low, with a range of $9.20 to $10.00, driven by growth deceleration and competitive losses. The Base Case is most likely, hinging on the assumption that generative AI remains a narrative overhang rather than an immediate, material threat to financials.
PATH appears fairly valued to slightly undervalued based on its forward earnings potential. The forward P/E of 11.6x is a significant discount to the trailing P/E of 24.0x, implying the market expects strong profit growth from the Q4 net income of $104.5M. Compared to its own history, where P/E ratios have been in the 90s, the current multiple is deeply discounted. This discount, however, directly prices in the competitive risks from generative AI. The market is paying a fair price for a profitable growth story that carries an existential overhang, making it neither egregiously expensive nor a deep-value bargain.
PATH is a high-risk, high-potential-reward stock that is not a clear-cut good buy for all investors. For risk-tolerant investors with a long-term horizon, the current price offers an entry into a fundamentally sound company with strong profitability (21.7% net margin), a pristine balance sheet, and a reasonable forward P/E of 11.6x. However, the significant downside risk, illustrated by the -51.4% max drawdown and persistent bearish sentiment (short ratio 3.28), makes it unsuitable for conservative portfolios. It could be a good buy for those who believe the generative AI threat is overblown and that UiPath will successfully transition to an AI-agent platform.
PATH is unsuitable for short-term trading due to its high volatility (beta 0.968, -51.4% max drawdown) and the lack of near-term bullish catalysts, as reflected in predominant analyst Hold ratings. It is a long-term investment for investors willing to hold for 3-5 years to see if the company's pivot to agentic AI succeeds. The strong cash flow and lack of debt provide stability for a long-term hold, but the investor must be prepared for significant price swings. A minimum holding period of 18-24 months is suggested to allow for several quarterly reports that can validate or invalidate the growth trajectory and competitive positioning.
